Researchers from Johns Hopkins have identified a marker, Mig6, that in early studies has been able to predict longer survival among patients taking the EGFR tyrosine kinase inhibitors gefitinib (Astra Zeneca's Iressa) and erlotinib (Genenetech's Tarceva).
Originally published May 14.
Smoking, most people have come to accept, is a major cause of lung cancer. But each year in the US, up to 24,000 men and women who have never smoked still end up dying from the disease.
Using a pharmacogenetic strategy to home in on a molecularly defined non-small cell lung cancer patient population, researchers have shown in a clinical trial that the investigational EGFR inhibitor afatinib significantly prolongs survival in patients with EGFR-mutated tumors.